🔎 Trials Near Me

Почетна › Akutna mijeloidna leukemija › Kanzas › Kansas City

Kliničke studije za Akutna mijeloidna leukemija u gradu Kansas City, KS

12 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u gradu Kansas City i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Тражи се учесникФаза 1
  • KU Cancer Center, Kansas City
Узраст 65 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06552416

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • University of Kansas Cancer Center, Kansas City
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • University of Kansas Cancer Center, Kansas City
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 3
  • US-Kansas City KS-KUMC, Kansas City
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07223814

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
  • Veteran Administration Eastern Kansas Healthcare, Leavenworth · 21 ми удаљено
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Тражи се учесникФаза 2
  • University of Kansas Cancer Center, Kansas City
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • University of Kansas Cancer Center, Kansas City
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • University of Kansas Cancer Center, Kansas City
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06672146

Ivosidenib as Post-HSCT Maintenance for AML

Тражи се учесникФаза 2
  • Kansas University Medical Center, Kansas City
Узраст од 18 до 75 · Оба пола · Ажурирано 5. 10. 2026. · NCT06707493

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Тражи се учесникФаза 1
  • University of Kansas Cancer Center, Kansas City
Узраст од 18 до 75 · Оба пола · Ажурирано 25. 8. 2026. · NCT05886049

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • The University of Kansas Cancer Center, Kansas City
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06001788

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Тражи се учесникФаза 1
  • University of Kansas Medical Center Research Institute, Inc., Kansas City
Узраст 18 и старији · Оба пола · Ажурирано 13. 4. 2026. · NCT06146257

Studije za Akutna mijeloidna leukemija u drugim gradovima

Ostale studije u gradu Kansas City

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.